Hutchmed (China) Limited Annual General Meeting Poll Results (5742J)

TIDMHCM

RNS Number : 5742J

Hutchmed (China) Limited

27 April 2022

Annual General Meeting held on April 27, 2022 - Poll Results

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 27, 2022: HUTCHMED (China) Limited (" HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual General Meeting ("AGM") held on April 27, 2022 were duly passed. The poll results of the resolutions were as follows:

 
                                                               Number of Votes (%)* 
                                                                                                  Passed by 
 Ordinary Resolutions                                     For        Against      Withheld(#)    Shareholders 
                                                    ------------  -----------  -------------- 
         To consider and adopt the audited 
          financial statements, and the 
          reports of the directors and independent 
          auditors for the year ended December 
 1.       31, 2021.                                  686,224,906     2,960        7,697,445          Yes 
                                                      (99.9996%)    (0.0004%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
         To re-elect Mr TO Chi Keung, Simon 
 2(A).    as a director.                             635,955,913   51,971,563     5,997,835          Yes 
                                                      (92.4452%)    (7.5548%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
         To re-elect Dr Weiguo SU as a 
 2(B).    director.                                  686,123,331   1,804,145      5,997,835          Yes 
                                                      (99.7377%)    (0.2623%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
         To re-elect Mr CHENG Chig Fung, 
 2(C).    Johnny as a director.                      685,947,446   1,980,030      5,997,835          Yes 
                                                      (99.7122%)    (0.2878%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
         To re-elect Dr Dan ELDAR as a 
 2(D).    director.                                  684,647,400   3,280,076      5,997,835          Yes 
                                                      (99.5232%)    (0.4768%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
         To re-elect Ms Edith SHIH as a 
 2(E).    director.                                  681,250,085   6,677,146      5,998,080          Yes 
                                                      (99.0294%)    (0.9706%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
         To re-elect Mr Paul Rutherford 
 2(F).    CARTER as a director.                      686,252,741   1,674,735      5,997,835          Yes 
                                                      (99.7566%)    (0.2434%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
         To re-elect Dr Karen Jean FERRANTE 
 2(G).    as a director.                             687,778,031    149,445       5,997,835          Yes 
                                                      (99.9783%)    (0.0217%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
         To re-elect Mr Graeme Allan JACK 
 2(H).    as a director.                             674,126,615   12,957,617     6,841,079          Yes 
                                                      (98.1141%)    (1.8859%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
         To re-elect Professor MOK Shu 
 2(I).    Kam, Tony as a director.                   670,413,452   17,501,649     6,010,210          Yes 
                                                      (97.4558%)    (2.5442%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
         To appoint PricewaterhouseCoopers 
          and PricewaterhouseCoopers Zhong 
          Tian LLP as the auditors of the 
          Company for Hong Kong financial 
          reporting and U.S. financial reporting 
          purposes, respectively, and to 
          authorize the Directors to fix 
 3.       the auditors' remuneration.                685,514,922   8,392,264       18,125            Yes 
                                                      (98.7906%)    (1.2094%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
 Special Resolution 
         To grant a general mandate to 
          the directors of the Company to 
 4.       issue additional shares.^                  683,701,055   4,221,351      6,002,905          Yes 
                                                      (99.3864%)    (0.6136%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
 Ordinary Resolutions 
         To grant a general mandate to 
          the directors of the Company to 
 5(1).    repurchase shares of the Company.^         687,914,356     7,770        6,003,185          Yes 
                                                      (99.9989%)    (0.0011%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
         To refresh the scheme mandate 
          limit under the Long Term Incentive 
 5(2).    Plan.^                                     601,082,095   53,973,751    38,869,465          Yes 
                                                      (91.7604%)    (8.2396%) 
        ------------------------------------------  ------------  -----------  --------------  -------------- 
 

* Percentages rounded to 4 decimal places

(#) A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.

^ The full text of Resolutions 4 and 5 are set out in the Notice of AGM.

All directors of the Company, namely Mr TO Chi Keung, Simon, Dr Weiguo SU, Mr CHENG Chig Fung, Johnny, Dr Dan ELDAR, Ms Edith SHIH, Mr Paul Rutherford CARTER, Dr Karen Jean FERRANTE, Mr Graeme Allan JACK and Professor MOK Shu Kam, Tony, attended the AGM, either in person or by means of electronic facilities.

Notes:

(1) Number of shares entitling the holders to attend and vote on all the resolutions at the AGM: 864,530,850 shares.

(2) Number of shares entitling the holders to attend and abstain from voting in favour as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") at the AGM: Nil.

(3) Number of shares for holders required under the Listing Rules to abstain from voting at the AGM: Nil.

(4) The scrutineer for the poll at the AGM was Computershare Investor Services (Jersey) Limited, the Principal Share Registrar of the Company.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of about 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch--med.com or follow us on LinkedIn .

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President      [phone] 
  Annie Cheng, Vice President          [phone] 
 
Media Enquiries 
  Americas - Brad Miles,               [phone] (Mobile) 
   Solebury Trout                       [e-mail] 
  Europe - Ben Atwell / Alex Shaw,     [phone] / [phone] (Mobile) / [phone] (Mobile) 
   FTI Consulting                       [e-mail] 
  Asia - Zhou Yi,                      [phone] (Mobile) 
   Brunswick                            [e-mail] 
 
Nominated Advisor 
  Atholl Tweedie / Freddy Crossley , 
   Panmure Gordon (UK) Limited         [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFLFLVSDIDFIF

(END) Dow Jones Newswires

April 27, 2022 09:30 ET (13:30 GMT)